U.S. Software Stock News

NasdaqGS:ANGO
NasdaqGS:ANGOMedical Equipment

AngioDynamics (ANGO) EPS Loss Of US$0.26 Tests Optimistic Profit Turnaround Narratives

AngioDynamics (ANGO) has opened Q2 2026 earnings season with Q1 fiscal 2026 revenue of US$75.7 million and a basic EPS loss of US$0.26, as the market weighs those results against a current share price of US$11.44. Over recent quarters the company has reported revenue of US$67.5 million in Q1 2025, US$80.2 million in Q4 2025, and US$75.7 million in Q1 2026, while basic EPS losses moved from US$0.31 to US$0.15 and then to US$0.26. This keeps the focus on the company’s path back toward...
NYSE:FDS
NYSE:FDSCapital Markets

FactSet Research Systems Q1 2026 Net Margin Strength Reinforces Bullish Profitability Narratives

FactSet Research Systems (FDS) opened fiscal Q1 2026 with revenue of US$607.6 million and basic EPS of US$4.08, setting the tone for another period where profit trends are front and center for investors. Over the past six quarters, the company has seen revenue move from US$562.2 million in Q4 2024 to US$607.6 million in Q1 2026, while basic EPS increased from US$2.35 to just over US$4.00, with trailing twelve month EPS at US$15.87. With net profit margins running in the mid 20% range over the...
NYSE:VIRT
NYSE:VIRTCapital Markets

Is Virtu Financial (VIRT) Attractively Priced After Mixed Share Price Returns?

If you are wondering whether Virtu Financial's current share price still reflects good value, it helps to step back and look at what the recent returns and our valuation checks are really saying. The stock last closed at US$33.17, with a 7 day return of a 2.4% decline, a 30 day return of a 6.2% decline, a 1 year return of a 6.0% decline, and a 72.3% return over 3 years and a 65.2% return over 5 years. These mixed returns sit against an ongoing flow of market commentary about liquidity...
NasdaqGS:ROIV
NasdaqGS:ROIVBiotechs

A Look At Roivant Sciences (ROIV) Valuation After Brepocitinib Timeline Acceleration And Profitability Outlook Shift

Roivant Sciences (ROIV) is back in focus after recent analyst commentary related to its lead drug candidate, brepocitinib. The company now has accelerated timelines along with updated expectations around costs and future profitability. See our latest analysis for Roivant Sciences. Roivant’s shares have been volatile around the recent brepocitinib updates, with the latest share price at US$21.30, a 90 day share price return of 32.88% and a 1 year total shareholder return of 84.90%. This...
NasdaqGS:LOT
NasdaqGS:LOTAuto

Assessing Lotus Technology (NasdaqGS:LOT) Valuation After Independent Auditor Change

Auditor change puts Lotus Technology (NasdaqGS:LOT) under a governance spotlight Lotus Technology (NasdaqGS:LOT) has replaced KPMG Huazhen LLP with Grant Thornton Zhitong Certified Public Accountants LLP as its independent auditor, a governance development that can shape how investors assess the company’s financial reporting. See our latest analysis for Lotus Technology. The auditor change follows a volatile period for Lotus Technology, with the $1.50 share price sitting above recent lows, a...
NYSE:KRC
NYSE:KRCOffice REITs

UCSF’s 16.5-Year Lease at Oyster Point Might Change The Case For Investing In Kilroy Realty (KRC)

Kilroy Realty has announced that, during 2025, it executed an additional 300,000 square feet of leases at Kilroy Oyster Point Phase 2, including a 16.5-year agreement with the University of California, San Francisco for about 280,000 square feet and a 20,000 square foot headquarters lease with a genomic sequencing foundry, bringing the project to roughly 44% leased. This long-duration commitment from UCSF, coupled with a life sciences headquarters tenant, underscores growing institutional...
NasdaqGS:LAUR
NasdaqGS:LAURConsumer Services

How Strong Online Growth and Raised 2025 Outlook Will Impact Laureate Education (LAUR) Investors

In the past few days, Laureate Education reported an 8.6% year-on-year revenue increase that exceeded analyst expectations by 3.7%, supported by strong fully online offerings in Peru and continued expansion in Mexico despite a softer macro backdrop. This performance prompted Laureate to raise its full-year 2025 outlook, signaling management’s increased confidence in the company’s trajectory amid favorable currency trends. We’ll now explore how the raised 2025 outlook, driven by online...
NYSE:HIMS
NYSE:HIMSHealthcare

3 Stocks That May Be Trading Below Their Estimated Value

As the U.S. stock market continues to reach new heights, with the Dow Jones Industrial Average hitting an all-time high for the second consecutive day, investors are keenly observing opportunities that may be overlooked amidst this bullish momentum. In such a thriving environment, identifying stocks that might be trading below their estimated value can offer potential avenues for growth and diversification within a well-rounded investment strategy.
NasdaqCM:MVST
NasdaqCM:MVSTMachinery

Insiders Favor These 3 High Growth Stocks

As the Dow Jones Industrial Average hits an all-time high for the second consecutive day, buoyed by recent geopolitical events, investors are closely watching how these developments impact market dynamics. In such a robust environment, stocks with strong growth potential and high insider ownership often attract attention as they suggest confidence from those closest to the company's operations.
NYSE:CINT
NYSE:CINTIT

NeoVolta Leads The Charge With These 3 Penny Stock Contenders

As the Dow Jones Industrial Average hits an all-time high for the second consecutive day, investors are closely watching market dynamics and seeking opportunities in lesser-known segments. Penny stocks, while often considered a relic of past trading days, still hold potential for those willing to explore smaller or newer companies with solid financials. This article highlights three penny stock contenders that exemplify strong balance sheets and fundamentals, offering a chance to uncover...
NasdaqGM:CLMB
NasdaqGM:CLMBElectronic

US Undiscovered Gems To Explore In January 2026

As the Dow Jones Industrial Average reaches new record highs, bolstered by recent geopolitical developments, investors are increasingly turning their attention to the potential of small-cap stocks in the United States. In this environment of heightened market activity and economic optimism, identifying promising yet overlooked companies can offer unique opportunities for growth.
NasdaqGS:CFLT
NasdaqGS:CFLTSoftware

Assessing Confluent (CFLT) Valuation After A Strong Three Month Share Price Run

Confluent (CFLT) has been drawing investor attention after a recent stretch of positive returns, including gains over the past month and past 3 months, prompting fresh questions about how its current valuation stacks up. See our latest analysis for Confluent. The recent 30-day share price return of 30.29% and 90-day share price return of 35.20% suggest momentum has been building. The 1-year total shareholder return of 4.69% and 3-year total shareholder return of 46.86% provide a longer-term...